Claxton Copeland III Recognized for Excellence in Clinical Research
Claxton Copeland III has been selected for inclusion in Marquis Who’s Who, a prestigious recognition that highlights individuals based on their accomplishments, visibility, and impact within their respective fields. His selection underscores his significant contributions to clinical research and his ongoing commitment to advancing medical science.
As the owner and director of Optimal Research Sites (ORS) LLC, Mr. Copeland has been instrumental in shaping the clinical research landscape. Leading a dedicated team that includes Kimberlee Del Campo, Roy Richardson, and Antonio Rivera, he has helped drive ORS’s growth and success. Based in Orange City, Florida, the company specializes in conducting phase I-IV clinical trials for new medications developed by pharmaceutical and biotech firms. Since taking the helm in 2021, Mr. Copeland has ensured that ORS provides accessible and comfortable services for trial participants while maintaining rigorous regulatory and compliance standards. His leadership extends to overseeing clinical operations, ensuring data integrity, and fostering collaborations with health care professionals.
Journey in Clinical Research
Mr. Copeland’s journey into the clinical research field began in 2016 when he started as a research assistant. This role provided him with invaluable hands-on experience working with one of Florida’s largest research networks, which earned a reputation as a top 10 enroller for Pfizer, Moderna, and Novavax COVID-19 vaccine trials. During the pandemic, his team played a pivotal role in producing critical vaccine safety and efficacy data. Pfizer recognized these contributions with multiple Appreciation Awards, acknowledging the team’s efforts in accelerating vaccine development and distribution.
Beyond his direct research involvement, Mr. Copeland has been a strong advocate for participant safety, diversity in clinical trials, and improving overall trial accessibility. He has worked tirelessly to ensure that ORS remains a leader in ethical and patient-focused research. By fostering an environment of transparency and trust, he has helped make clinical trials more inclusive and effective, paving the way for more representative medical advancements.
Academic and Professional Credentials
Mr. Copeland holds a bachelor’s degree in neuropsychology from the University of Central Florida. His educational background provided him with a deep understanding of human cognition and behavior, which has been instrumental in his approach to clinical research. His expertise in neuropsychology allows him to assess clinical trial methodologies with a keen eye, ensuring studies are both scientifically sound and participant-friendly.
In addition to his degree, Mr. Copeland holds certification as a clinical research coordinator from the Association of Clinical Research Professionals (ACRP). He is also certified in Good Laboratory Practices (GLP), a crucial qualification that ensures research integrity and regulatory compliance. His commitment to professional development and adherence to the highest research standards have set him apart in the field.
Recognitions and Community Contributions
Mr. Copeland’s efforts have not gone unnoticed. In 2024, he was named one of Orlando Family Magazine’s Men of the Year, a testament to his impact on the community and his dedication to advancing health care accessibility. This recognition highlights his contributions beyond the laboratory, acknowledging his efforts in fostering diversity in clinical trials and improving patient experiences.
Furthermore, Mr. Copeland actively participates in the Association of Clinical Research Professionals, where he engages in discussions on industry advancements and best practices. His membership in this esteemed organization further demonstrates his commitment to staying at the forefront of clinical research.
Leadership and Future Goals
At the heart of Mr. Copeland’s success is his ability to cultivate meaningful relationships and build strong professional networks. He attributes much of his growth to his ability to connect with others, whether it be colleagues, research participants, or industry stakeholders. His leadership style prioritizes collaboration, ensuring that ORS operates efficiently while maintaining a patient-centric approach.
The future, Mr. Copeland and his partners—Kimberlee Del Campo, Roy Richardson, and Antonio Rivera—plan to expand ORS’s capabilities. They are currently preparing to open a second overnight facility for phase one clinical trials involving human subjects. This expansion aims to accommodate more participants, advance research efforts, and strengthen ORS’s ability to contribute to groundbreaking medical discoveries.
By continuing to innovate and push the boundaries of clinical research, Mr. Copeland remains a driving force in the field. His unwavering dedication to scientific integrity, participant welfare, and research excellence ensures that he will remain a pivotal figure in clinical research for years to come. His inclusion in Marquis Who’s Who is a well-deserved recognition of his tireless work and significant contributions to advancing medical science.
